StopAfib.org has announced the Top Ten Atrial Fibrillation Videos of 2011. Afib stroke prevention again topped the list, with stories about warfarin (Coumadin), alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto), and the CHADS2 and CHA2DS2-VASc scoring tools for determining whether anticoagulants are needed. Other popular topics included sleep apnea, catheter ablation, and maze procedures (surgical …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More
StopAfib.org has published the 2010 Most Popular Atrial Fibrillation News Stories and Videos List. Stroke prevention topped the list and included stories about warfarin (Coumadin) and alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto). Other popular topics included the new European atrial fibrillation guidelines, new antiarrhythmic medications, updates on catheter ablation and afib surgery, and …
Read More
Whether you're an atrial fibrillation patient or caregiver, or are just interested in learning more about afib, check out the new Get Started Learning About Atrial Fibrillation Guide at StopAfib.org. You'll find a wealth of information, including: what afib is and the problems it causes, including stroke and congestive heart failure information about an afib …
Read More
StopAfib.org interviews Dr. Peter Kowey See the full transcript at: www.stopafib.org In this video interview at Boston Atrial Fibrillation Symposium 2010, Dr. Peter Kowey talked about a number of exciting new things in the atrial fibrillation world, including the Cabana clinical trials, the Safari catheter ablation registry, dronedarone as a …
Read More
Not all atrial fibrillation patients are candidates for an ablation, either catheter ablation or surgical ablation, such as the maze or mini maze procedures. Thus their stroke risk remains high. We recently wrote about the FDA’s approval of the AtriClip device, which is implanted during open heart surgery and reduces stroke risk by occluding (closing …
Read More
AF patients are generally at a higher risk for stroke and thus may have to take anticoagulant medications, such as Coumadin or warfarin, to manage their afib-related stroke risk. With the FDA's recent approval of AtriCure's AtriClip device that is implanted during open heart surgery, afib patients and their doctors may now have another way …
Read More